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Objectives: To identify the impact of lower extremity
revascularization or amputation on 30-day mortality in
patients with preoperative do not resuscitate orders
documented.
Methods: Patients were identified from the 2005-
2008 ACS NSQIP datafile using CPT codes. Group-wise
comparisons based on DNR status were performed using
t-tests and 2. Associations between preoperative DNR
status, operative management (categorically evaluated as
revascularization versus amputation), and mortality were
evaluated using logistic regression.
Results: 15,541 operations were identified, of which
9417 were revascularizations and 6,124 were major ampu-
tations. 526 patients were DNR (1.1% of revasculariza-
tions; 6.8% of amputations. DNR patients were older and
had a greater prevalence of preoperative comorbid condi-
tions and abnormal laboratory data. Perioperative mortality
was 22.2% for DNR versus 5% for non-DNR patients
[univariate OR (95% CI) for DNR status: 5.4 (4.4-6.6);
P0.0001]. Multivariable modeling adjusting for preoper-
ative differences in demographic, comorbidity, and labora-
tory data revealed an interaction between DNR status and
procedural management (P0.0013). DNR status was as-
sociated with increased mortality risk following both revas-
cularization [Estimated(OR)(95% CI):4.9 (2.9-8.3)] and
amputation [Estimated (OR)(95% CI):1.9 (1.4-2.5)].
Conclusions: DNR patients are at increased risk for
perioperative mortality following both lower extremity am-
putation and revascularization, and this association be-
tween DNR status and mortality persists after adjusting for
differences in other risk factors. The differential effect on
mortality risk based on procedural management implies
greater risk for DNR patients undergoing revasculariza-
tion, but may reflect the influence of DNR status on
procedure selection given greater prevalence of DNR status
among these patients. DNR status should be considered
during preoperative risk assessment and may inform preop-
erative counseling and decision making.
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Objectives: To evaluate the safety and efficacy of trans-
plantation of purified peripheral blood CD34 cells in
treatment of no-option critical limb ischemia (NOCLI).
Methods: From May 2009 to Nov. 2010, 15 NOCLI
cases were included, 11 with thromboangitis, 2 atheroscle-
rosis obliterans, and 2 vasculitis, mean age 4415years.
G-CSF was subcutaneously injected for 5 days before
apheresis. CD34 cells were isolated with CliniMACS
system, and then intramuscularly injected into calf and foot.
Results: Technical success was achieved in all cases.
Major amputation was performed in 2 cases postopera-
tively, and the salvage rate was 87%. The mean number of
transplanted cells was (7.844.17) 105/kg. The fol-
low-up was accomplished in all cases, ranging from 1-19
months (mean 85months). One month after transplanta-
tion, the rest pain was obviously relieved in 11 cases, and
theWong-Baker FACES pain rating scale score significantly
decreased from 72 to 11, P0.0000. At 6 months, the
pain-free walking distance on treadmill measured in 8 eli-
gible cases was significantly improved from 3.03.0 min to
17.910.6 min (P0.001); the ankle-brachial index in-
creased from 0.450.22 to 0.690.13 ( P0.007); trans-
cutaneous partial oxygen pressure rose from 2912mmHg
to 579mmHg (P0.0002). Of 9 cases with the foot
ulcer, it was healed in 6 patients at 43months and appar-
ently shrank in 3. No serious complications were observed
either perioperatively or during the follow-up.
Conclusions: Transplantation of purified peripheral
blood CD34 cells appeared to be safe and effective in
treatment of NOCLI, and mid-to-long-term results is
pending further investigation.
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Objectives: Treatment options for aorto-ilac occlusive
disease (AIOD) include open and endovascular treatment.
We performed a meta-analysis of studies reporting the
treatment outcomes for AIOD.
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Methods: Peer-reviewed published studies on open
and endovascular treatment for AIOD since 1989 were
identified in PubMed, Medline, and EBSCOHost. Reports
were thoroughly analyzed, and those not meeting the
pre-defined inclusion criteria were excluded.
Results: Thirty-seven open studies with 6,618 patients
and 31 endovascular studies with 1,932 patients were in-
cluded in our analysis. Mean age was 60.7 years for open
and 60.5 years for endovascular patients. More patients
presented with critical limb ischemia in the open group
(35.5% vs. 23.6%, Odds Ratio [OR]: 1.8, p0.001) than
with claudication (65.6% vs. 76.2%, OR: 0.6, p0.001).
Mean overall follow-up time in months was greater in the
open than endovascular group (42.2 vs. 26.2, p0.001).
Poor preoperative runoff was greater in the open group
(47.1% vs. 25.0%, OR: 2.8, p0.001). No differences in
length of hospital stay (LOS) or increase in ankle-brachial
index were detected. The open group experienced more
systemic (9.5% vs. 3.5%, OR: 2.9, p0.001) than local
complications (4.6% vs. 13.3%, OR: 0.3, p0.001). Mor-
tality was greater in the open group (2.6% vs. 0.5%, OR:
5.3, p0.001), and secondary procedures were required
less frequently (4.1% vs. 8.5%, OR: 0.5, p0.001). Primary
patency rates at 1, 3, and 5 years were greater in the open
group (94.8% vs. 85.7%, OR: 3.0, p0.001; 87.7% vs.
78.9%, OR: 1.6, p0.001; 86.2% vs. 69.5%, OR: 2.4,
p0.001, respectively).
Conclusions: To our knowledge, this is the first sys-
tematic review comparing open and endovascular treat-
ment options for AIOD. These results demonstrate supe-
rior durability and equivalent LOS for open treatment with
an increased risk for systemic complications and mortality
when compared to the endovascular approach. Further
clinical studies are necessary to better characterize these
two treatment options.
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Objectives: Acute upper extremity ischemia is associ-
ated with substantial functional impairment. For many
years, surgical intervention has been the treatment of
choice, but perioperative mortality is up to 19%. Reports on
primary thrombolysis to treat acute upper extremity isch-
emia are scarce.
Methods: During a 4-year period all patients with
acute nontraumatic upper extremity ischemia (Rutherford
class 1 or 2a) undergoing catheter-directed thrombolysis as
first line treatment were identified. One month follow-up
consisted of duplex-scanning of the treated arm.
Results: From 2006 to 2010, 28 patients (22 women,
median age 60 years, range 33-80) were treated with
thrombolysis for acute upper extremity ischemia. Occlu-
sions were localised as follows: subclavian artery (n8),
brachial artery (n6), radial and/or ulnar arteries (n11),
bypass graft (n3). Length of the occlusions was more
than 8 cm. Causes of occlusion were thromboembolic
(n15), arterial thoracic outlet syndrome (n4), paraneo-
plastic (n1), and unknown (n8). Placement of a throm-
bolysis catheter was unsuccessful in only 1 out of 28 pa-
tients. Median duration of thrombolysis was 24 hours
(18-96). In 17 out of 28 patients complete lysis was
achieved, with complete resolution of symptoms. In 4
patients partial lysis was achieved; these patients were
asymptomatic and therefore treated conservatively. In 7
patients no lysis was achieved; these were treated with
embolectomy (n4), amputation (n2), and conserva-
tively (n1). During thrombolysis 1 patient had a throm-
boembolic complication of the lower limb, that was treated
successfully with thrombolysis and 1 had a transient isch-
emic attack.
At 1-month follow-up 2 reocclusions had occurred,
that were treated successfully with percutaneous translumi-
nal angioplasty (n1) and thrombolysis (n1).
Conclusions: Based on our results catheter-directed
thrombolysis is effective and safe as first line treatment of
acute nontraumatic upper extremity ischemia, in order to
prevent or limit surgical intervention.
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Objectives: This study assesses the effects of end
stage renal disease (ESRD) on diabetic patients under-
going percutaneous interventions for critical limb isch-
emia (CLI).
Methods: Eighty-three diabetic patients (15 with
ESRD) requiring infrainguinal interventions were studied.
Diabetics with and without ESRD were compared over 24
months. Statistical analysis was conducted with SPSS soft-
ware (SPSS Inc. Chicago, IL).
Results: Diabetic patients with ESRD presented with
CLI at an earlier age (64.5 vs. 71.8 years, p0.012) and
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